Dietary Supplement
AXA1125
AXA1125 is a dietary supplement with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
2
67%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
NCT05152849
unknownphase_2
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
completednot_applicable
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04073368
Clinical Trials (3)
Showing 3 of 3 trials
NCT05152849Phase 2
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
NCT04880187Phase 2
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04073368Not Applicable
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
All 3 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 3